Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2007-10-23
2007-10-23
Tsang, Cecilia J. (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
Reexamination Certificate
active
10513083
ABSTRACT:
The present invention relates to agonists and antagonists of gonadotropin-releasing hormone-2 (GnRH-2), which regulates the activity of GnRH-2 by specifically binding to GnRH-2 receptors, and uses thereof. The pharmaceutical compositions comprising the GnRH-2 agonists and antagonists according to the present invention are useful for the treatment of reproductive physiology diseases and steroid-related cancer cells because they specifically bind to the GnRH-2 receptors, and they are also usefully applicable to the raising industry of non-mammalian animals, i.e., birds and fish.
REFERENCES:
White et al., “Second gene for gonadotropin-releasing hormone in humans.” PNAS, 1998, 95, 305-9.
Neill et al., “A gonadotropin-releasing hormone (GnRH) receptor specific for GnRH II in primates.” Biochem. Biophys. Res. Com., 2001, 282, 1012-8.
Lescheid et al., “A second form of gonadotropin-releasing hormone (GnRH) with characteristics of chicken GnRH-II is present in the primate brain.” Endo., 1997, 138, 5618-29.
Kang et al., “Differential regulation of two forms of gonadotropin-releasing hormone messenger ribonucleic acid in human granulosa-luteal cells.” Endo., 2001, 142, 182-92.
Wang et al., “Preferential ligand selectivity of the monkey type-II gonadotropin-releasing hormone (GnRH) receptor for GnRH-2 and its analogs.” Mol. Cell Endo., 2003, 209, 33-42.
Maiti et al., “GnRH-II analogs for selective activation and inhibition of non-mammalian and type-II mammalian GnRH receptors.” Mol. Cells, 2003, 16, 173-9.
Chou et al. “Differential effects of gonadotropin-releasing hormone I and II on the urokinase-type plasminogen activator/plasminogen activator inhibitor system in human decidual stromal cells in vitro.” J. Clin. End. Met., 2002,87,5594-603.
Emons et al. “GnRH antagonists in the treatment of gynecological and breast cancers.” Endo.-Rel. Canc., 2003, 10, 291-9.
Grundker et al., “Biology of the gonadotropin-releasing hormone system in gynecological cancers.” Eur. J. Endo., 2002, 146, 1-14.
Ginalski et al. “Practical lessons from protein structure prediction.” Nuc. Ac. Res., 2005, 33, 1874-1891.
Rudinger “Characteristic of the amino acids as components of a peptide hormone sequence.” (Peptide Hormones (Ed. J.A. Parson). University Park Press. Baltimore, 1976, pp. 1-7.
Pitt et al. “Single amino acid substitution mutants of Klebsiella pneumoniae singma54 defective in transcription” Nuc. Ac. Res., 2000, 28, 4419-4427.
Bradley et al. “Limits of Cooperativity in a Structurally Modular Protein: Response of the Notch Ankyrin Domain to Analogous Alanine Substitutions in Each Repeat” J. Mol. Biol., 2002, 324, 373-386.
Flanagan et al. “Truncated staphyloccal nuclease in compact but disordered” Proc. Natl. Acad. Sci. USA, 1992, 89, 748-752.
Sawai et al. “Impact of single-residue mutations on the structure and function of ovispirin
ovispirin antimicrobial peptides” Prot. Engin., 2002, 15, 225-232.
Schnog et al. “Sickle cell disease; a general overview” J. Med., 2004, 62, 364-374.
Kwon Hyuk-Bang
Seong Jae-Young
Bradley Christina M.
Jones Day
Neurogenex Co., Ltd.
Tsang Cecilia J.
LandOfFree
Agonists and antagonists of gonadotropin-releasing... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Agonists and antagonists of gonadotropin-releasing..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Agonists and antagonists of gonadotropin-releasing... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3902483